PRNewsWire
16 Jul 2026, 23:52 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Celcuity's commercial launch of Revtorpyk is scheduled for late Q3 2026, which is later than analyst expectations. — Delayed commercialization timelines negatively impact near-term revenue forecasts and investor sentiment.
-0.60Celcuity Inc. received FDA approval for its breast cancer therapy, Revtorpyk. — FDA approval is a primary value driver for biotech companies, enabling the transition to commercial revenue.
+0.50Pomerantz LLP is investigating Celcuity for potential securities fraud or unlawful business practices following the launch timeline announcement. — The initiation of a class action investigation creates legal overhang and risk of future financial liabilities.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
Company is facing a securities fraud investigation and a stock price drop due to a delayed product launch timeline.
A class action lawsuit has been filed against the company.
The company is the subject of an investigation into claims on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
